Dynamic phosphorylation of VE-cadherin Y685 throughout mouse estrous cycle in ovary and uterus

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 3, 2014, Pages

  Sidibé, Adama ^a,b,c   Polena, Helena ^a,b,c   Razanajatovo, Jeremy ^a,b,c   Mannic, Tiphaine ^a,b,c   Chaumontel, Nicolas ^a,b,c   Bama, Soumalamaya ^a,b,c   Maréchal, Irène ^a,b,c   Huber, Philippe ^a,b,c   Gulino Debrac, Danielle ^a,b,c   Bouillet, Laurence ^a,b,c,d   Vilgrain, Isabelle ^a,b,c  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c CEA GRENOBLE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Estrous cycle; Tyrosine kinase; Vascular remodeling; VE cadherin phosphorylation in vivo

Indexed keywords

CHORIONIC GONADOTROPIN; PHOSPHOSPECIFIC ANTIBODY; SERIC GONADOTROPIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; CADHERIN; LEUKOCYTE ANTIGEN; PROTEIN TYROSINE KINASE; TYROSINE;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; DIESTRUS; ENDOTHELIUM CELL; ESTRUS; ESTRUS CYCLE; FEMALE; HORMONAL REGULATION; METESTRUS; MOUSE; NONHUMAN; OVARY; PRIORITY JOURNAL; PROESTRUS; PROTEIN PHOSPHORYLATION; UTERUS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; TIME; VASCULAR REMODELING; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; CADHERINS; CHORIONIC GONADOTROPIN; ESTROUS CYCLE; FEMALE; GONADOTROPINS, EQUINE; MICE, INBRED C57BL; OVARY; PHOSPHORYLATION; SRC-FAMILY KINASES; TIME FACTORS; TYROSINE; UTERUS; VASCULAR REMODELING;

EID: 84905223564     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00773.2013     Document Type: Article

References (29)

1. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451: 1008-1012, 2008.
2. Baumeister U, Funke R, Ebnet K, Vorschmitt H, Koch S, Vestweber D. Association of Csk to VE-cadherin and inhibition of cell proliferation. EMBO J 24: 1686-1695, 2005.
3. Butcher RL, Collins WE, Fugo NW. Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17β throughout the 4-day estrous cycle of the rat. Endocrinology 94: 1704-1708, 1974.
4. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β. Cancer Res 62: 4977-4984, 2002.
5. Caligioni CS. Assessing reproductive status/stages in mice. Curr Protoc Neurosci Appendix 4: Appendix 4I, 2009.
6. Chakraborty I, Das SK, Dey SK. Differential expression of vascular endothelial growth factor and its receptor mRNAs in the mouse uterus around the time of implantation. J Endocrinol 147: 339-352, 1995.
7. Daniel JM, Reynolds AB. Tyrosine phosphorylation and cadherin/catenin function. Bioessays 19: 883-891, 1997.
8. Dejana E, Vestweber D. The role of VE-cadherin in vascular morphogenesis and permeability control. Prog Mol Biol Transl Sci 116: 119-144, 2013.
9. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947-959, 1998.
10. Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NR. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J 22: 3571-3580, 2012.
11. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340, 1998.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
13. Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141: 995-1000, 2000.
14. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143: 4339-4348, 2002.
15. Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Applanat M. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J Endocrinol 188: 91-99, 2006.
16. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190, 2000.
17. Kazi AA, Koos RD. Estrogen-induced activation of hypoxia-inducible factor-1α, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 148: 2363-2374, 2007.
18. Lambeng N, Wallez Y, Rampon C, Cand F, Christe G, Gulino-Debrac D, Vilgrain I, Huber P. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues. Circ Res 96: 384-391, 2005.
19. Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, Sigismund S, Ristagno G, Maddaluno L, Koh GY, Franco D, Kurtcuoglu V, Poulikakos D, Baluk P, McDonald D, Grazia Lampugnani M, Dejana E. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun 3: 1208, 2012.
20. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of p120-and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem 280: 31906-31912, 2005.
21. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 16: 488-496, 1996.
22. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. FASEB J 6: 886-892, 1992.
23. Staley K, Scharfman H. A woman's prerogative. Nat Neurosci 8: 697-699, 2005.
24. Turowski P, Martinelli R, Crawford R, Wateridge D, Papageorgiou AP, Lampugnani MG, Gamp AC, Vestweber D, Adamson P, Dejana E, Greenwood J. Phosphorylation of vascular endothelial cadherin controls lymphocyte emigration. J Cell Sci 121: 29-37, 2008.
25. Vilgrain I, Sidibé A, Polena H, Cand F, Mannic T, Arboleas M, Boccard S, Baudet A, Gulino-Debrac D, Bouillet L, Quesada JL, Mendoza C, Lebas JF, Pelletier L, Berger F. Evidence for posttranslational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. PLoS One 8: e80056, 2013.
26. Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S, Vilgrain I, Huber P. Src kinase phosphorylates vascular endothelialcadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26: 1067-1077, 2007.
27. Wayne CM, Fan HY, Cheng X, Richards JS. Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. Mol Endocrinol 21: 1940-1957, 2007.
28. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 113: 885-894, 2004.
29. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV, Kitajewski J. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J Clin Invest 112: 659-669, 2003.